Epidermolizis Bülloza ve Vitamin D
Özet
Kalıtsal epidermolizis bülloza (EB), deri frajilitesi ve mekanik travmalarla tetiklenen büllerle seyreden, nadir görülen bir genodermatozdur. Hastalık; EB simpleks, junktional EB, distrofik EB ve Kindler sendromu olmak üzere dört ana tipe ayrılır. Şiddetli formlarında özofagus darlığı, büyüme geriliği ve anemi gibi multisistemik ekstrakutanöz komplikasyonlar gelişebilir. Süreğen dejenerasyon ve rejenerasyon süreçleri yüksek kalori tüketimine yol açarken; kısıtlı mobilite, pansuman materyallerinin güneş ışığını engellemesi ve nutrisyonel yetersizlikler EB hastalarında ciddi D vitamini eksikliğine ve osteoporoza zemin hazırlar. D vitamini kemik metabolizmasının ötesinde hücresel farklılaşma ve bağışıklıkta rol oynar; bu nedenle hastalarda düzenli D vitamini, kalsiyum ve fosfat monitörizasyonu ile takviyesi kritik önem taşır. Edinsel EB modellerinde oral kalsitriolün inflamasyonu ve otoantikorları baskıladığı, yaralarda ise topikal kalsipotriolün antimikrobiyal ve antineoplastik etkiler göstererek yara iyileşmesini hızlandırdığı saptanmıştır. Sonuç olarak EB hastalarında D vitamini eksikliği sık görülmekte, nutrisyonel ve topikal D vitamini uygulamaları umut verici klinik sonuçlar sunmaktadır.
Hereditary epidermolysis bullosa (EB) is a rare genodermatosis characterized by skin fragility and blisters triggered by mechanical trauma. The disease is classified into four main types: EB simplex, junctional EB, dystrophic EB, and Kindler syndrome. Severe forms can lead to multisystemic extracutaneous complications such as esophageal strictures, growth retardation, and anemia. While continuous degeneration and regeneration processes cause high caloric consumption, limited mobility, wound dressings blocking sunlight, and nutritional deficiencies predispose EB patients to severe vitamin D deficiency and osteoporosis. Beyond bone metabolism, vitamin D plays a role in cellular differentiation and immunity; therefore, regular monitoring and supplementation of vitamin D, calcium, and phosphate are critical. In acquired EB models, oral calcitriol has been shown to suppress inflammation and autoantibodies, while topical calcipotriol in wounds exerts antimicrobial and antineoplastic effects, accelerating wound healing. Consequently, vitamin D deficiency is common in EB patients, and nutritional as well as topical vitamin D applications provide promising clinical outcomes.
Referanslar
Fine JD, Johnson LB, Suchindran C, et al. The epidemiology of inherited epidermolysis bullosa. In. Fine JD, Bauer EA, McGuire J, Moshell A, (Eds.). Epidermolysis bullosa: clinical, epidemiologic, and laboratory advances and the findings of the national epidermolysis bullosa registry. 1999: 101-13. Johns Hopkins University Press, Baltimore.
Mellerio JE. Molecular pathology of the cutaneous basement membrane zone. Clin Exp Dermatol. 1999;24(1):25–32.
Has C, Liu L, Bolling MC, et al. Clinical practice guidelines for laboratory diagnosis of epidermolysis bullosa. Br J Dermatol. 2020;182(3):574–92.
Chen JSC, Yang A, Murrell DF. Prevalence and pathogenesis of osteopenia and osteoporosis in epidermolysis bullosa: An evidence-based review. Exp Dermatol. 2019;28(10):1122–30.
Rodari G, Guez S, Manzoni F, et al. Birmingham epidermolysis severity score and vitamin D status are associated with low BMD in children with epidermolysis bullosa. Osteoporos Int .2017;28(4):1385–92. doi.org/10.1007/s00198-016-3883-1
Yenamandra VK, Moss C, Sreenivas V, et al. Development of a clinical diagnostic matrix for characterizing inherited epidermolysis bullosa. Br J Dermatol. 2017;176(6):1624–32.
Almaani N, Liu L, Dopping-Hepenstal PJC, et al. Identical glycine substitution mutations in type VII collagen may underlie both dominant and recessive forms of dystrophic epidermolysis bullosa. Acta Derm Venereol. 2011;91(3):262–6.
Fine JD, Bruckner-Tuderman L, Eady RAJ, et al. Inherited epidermolysis bullosa: Updated recommendations on diagnosis and classification. J Am Acad Dermatol. 2014;70(6):1103–26. doi.org/10.1016/j.jaad.2014.01.903
Fine JD, Mellerio JE. Extracutaneous manifestations and complications of inherited epidermolysis bullosa. Part I. Epithelial associated tissues. J Am Acad Dermatol. 2009;61(3):367–84. doi.org/10.1016/j.jaad.2009.03.052
Fine JD, Mellerio JE. Extracutaneous manifestations and complications of inherited epidermolysis bullosa. Part II. Other organs. J Am Acad Dermatol. 2009;61(3):387–402. doi.org/10.1016/j.jaad.2009.03.053
Kanis JA. Osteoporosis III: Diagnosis of osteoporosis and assessment of fracture risk. Lancet. 2002;359(9321):1929–36.
Sambrook P, Cooper C. Osteoporosis. Lancet. 2006;367(9527):2010–8.
Navarro-Triviño FJ, Arias-Santiago S, Gilaberte-Calzada Y. Vitamin D and the Skin: A Review for Dermatologists. Actas Dermosifiliogr. 2019;110(4):262–72.
Washington DAP. Institute of Medicine, Food and Nutrition Board. Dietary reference intakes for calcium and vitamin D. 2010:4. National Academy Press, Washington, DC.
Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Guidelines for preventing and treating vitamin D deficiency and insufficiency revisited. J Clin Endocrinol Metab. 2012;97(4):1153–8.
Becker M, CA S. Epidermolysis bullosa dystrophica in children. Radiologic manifestations. Radiology. 1968;90(1):124–8.
Lara-Corrales AL. Bruckner JC. Salas Alanis, JE. et al. Monitoring to Prevent Complications: Anemia, Infections, Osteopenia, Failure to Thrive, Renal Disease, Squamous Cell Carcinoma, Cardiomyopathy. In. D. F. Murrell (Ed.), Springer. 2015: 667–85. Berlin Heidelberg, Berlin.
Reyes ML, Cattani A, Gajardo H, et al. Bone metabolism in children with epidermolysis bullosa. J Pediatr. 2002;140(4):467–9.
Fewtrell MS, Allgrove J, Gordon I, et al. Bone mineralization in children with epidermolysis bullosa. Br J Dermatol. 2006;154(5):959–62.
Salera S, Tadini G, Rossetti D, et al. A nutrition-based approach to epidermolysis bullosa: Causes, assessments, requirements and management. Clin Nutr. 2020;39(2):343–52.
Bruckner AL, Bedocs LA, Keiser E, et al. Correlates of low bone mass in children with generalized forms of epidermolysis bullosa. J Am Acad Dermatol. 2011;65(5):1001–9. doi.org/10.1016/j.jaad.2010.08.028
Reimer A, Hess M, Schwieger-Briel A, et al. Natural history of growth and anaemia in children with epidermolysis bullosa: a retrospective cohort study. Br J Dermatol. 2020;182(6):1437–48.
Fu T, Lingala B, Kent K, et al. Patterns of bone mineral acquisition in children with epidermolysis bullosa: A longitudinal study. Br J Dermatol. 2011;165(5):1081–6.
Hubbard L, Haynes L, Sklar M, et al. The challenges of meeting nutritional requirements in children and adults with epidermolysis bullosa: Proceedings of a multidisciplinary team study day. Clin Exp Dermatol. 2011;36(6):579–84.
Botelho J, Machado V, Proença L, et al. Vitamin D deficiency and oral health: A comprehensive review. Nutrients. 2020;12(5):1471.
Mehren CR, Gniadecki R. Epidermolysis bullosa acquisita: Current diagnosis and therapy. Dermatology Reports. 2011;3(3):2–5.
Tukaj S, Bieber K, Witte M, et al. Calcitriol Treatment Ameliorates Inflammation and Blistering in Mouse Models of Epidermolysis Bullosa Acquisita. J Invest Dermatol. 2018;138(2):301–9. doi.org/10.1016/j.jid.2017.09.009
Guttmann-Gruber C, Tockner B, Scharler C, et al. Low-dose calcipotriol can elicit wound closure, anti-microbial, and anti-neoplastic effects in epidermolysis bullosa keratinocytes. Sci Rep. 2018;8(1):1–14.
